AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Apoptosis Pathway Activation

Executive Summary: AT-406 (SM-406) is a small-molecule IAP inhibitor with high oral bioavailability, targeting XIAP, cIAP1, and cIAP2 at nanomolar affinities, and promoting apoptosis in tumor models (product; Yang et al., 2024). It induces rapid cIAP1 degradation and XIAP antagonism, resulting in caspase 3/7/9 activation and robust tumor cell death. In vitro, it sensitizes ovarian cancer cells to carboplatin, with IC50 values between 0.05–0.5 μg/mL under standard incubation (24 h, 37°C, 5% CO₂). In vivo, AT-406 achieves significant tumor growth inhibition and survival extension in mouse xenograft models of breast and ovarian cancer. Clinical data demonstrate oral AT-406 is well tolerated up to 900 mg/d in diverse cancer patients (A3019 kit).

Biological Rationale

Apoptosis is a tightly regulated process essential for normal development, tissue homeostasis, and immune defense (Yang et al., 2024). Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 block caspase activity, preventing programmed cell death in both physiological and pathological contexts. Elevated IAP expression is frequently observed in cancer, where it confers resistance to apoptosis and promotes tumor survival (AT-406: Uncovering IAP Inhibitor Roles). Disruption of IAP-caspase interactions restores cell death pathways, representing a validated strategy for targeted cancer therapy.

Mechanism of Action of AT-406 (SM-406)

AT-406 (SM-406) acts as a pan-IAP antagonist, binding to the BIR3 domains of XIAP (Ki = 66.4 nM), cIAP1 (Ki = 1.9 nM), and cIAP2 (Ki = 5.1 nM), with high specificity (A3019 kit). It mimics natural Smac/DIABLO peptides, competitively displacing IAPs from caspase 3, 7, and 9. This leads to rapid cIAP1 autoubiquitination and proteasomal degradation (Yang et al., 2024). Loss of cIAPs relieves inhibition on caspase-8 activation within the death-inducing signaling complex (DISC), and lowers the apoptotic threshold. The resulting caspase cascade executes cell death and suppresses tumor growth (see: AT-406: Uncovering IAP Inhibitor Roles, which expands on immune pathway crosstalk; this article clarifies direct molecular mechanisms).

Evidence & Benchmarks

• AT-406 exhibits nanomolar binding affinity to XIAP, cIAP1, and cIAP2 BIR domains (Ki = 66.4 nM, 1.9 nM, 5.1 nM, respectively) (ApexBio).
• AT-406 induces rapid cIAP1 protein degradation in cancer cells within 1–2 hours at 1 μM in DMSO (Yang et al., 2024).
• Human ovarian cancer cell line studies show AT-406 IC50 values ranging from 0.05–0.5 μg/mL after 24 h exposure (ApexBio).
• AT-406 sensitizes chemoresistant ovarian cancer cells to carboplatin, lowering the threshold for apoptosis in vitro (see: AT-406: Orally Bioavailable IAP Inhibitor; this article details quantitative synergy data).
• In vivo, AT-406 administered orally inhibits tumor progression and extends survival in mouse xenograft models of breast and ovarian cancer (doses and schedules as per protocol) (Yang et al., 2024).
• Clinical trials report that oral AT-406 is well tolerated up to 900 mg/day with manageable adverse events in patients with advanced malignancies (ApexBio).
• AT-406 is highly soluble in DMSO and ethanol (≥27.65 mg/mL) but insoluble in water; storage at –20°C is required (ApexBio).

Applications, Limits & Misconceptions

AT-406 is primarily used in apoptosis modulation studies, cancer biology, and drug development targeting the IAP family (AT-406: Applied IAP Inhibitor Workflows; this article updates experimental design considerations with new benchmarks). Its efficacy is prominent in models of ovarian and breast cancer, especially in overcoming chemoresistance. However, its performance depends on IAP expression levels, cell context, and the presence of functional caspase machinery.

Common Pitfalls or Misconceptions

• AT-406 is not effective in cell lines with deleted or mutated caspase 3, 7, or 9, as downstream execution is blocked.
• Water-based solvents are unsuitable for AT-406 stock preparation due to solubility limitations; DMSO or ethanol are required.
• AT-406 does not induce apoptosis in IAP-independent cell death contexts, such as necroptosis-dominant models.
• Excessive storage (>6 months or >–20°C) may reduce compound activity; use fresh solutions for critical assays.
• AT-406 is not a generic cytotoxin; its effects are specific to IAP-overexpressing, apoptosis-competent cells.

Workflow Integration & Parameters

AT-406 is supplied as a solid (MW 561.71), typically dissolved in DMSO (≥27.65 mg/mL) for cell-based assays. Working concentrations range from 0.1–3 μM, with standard exposure times of 24 hours at 37°C. For in vivo models, oral gavage is used at protocol-specified doses (refer to A3019 kit). Caspase activation and cell death endpoints are measured via luminescent or colorimetric assays. Integration with chemotherapy (e.g., carboplatin) is common for sensitization studies. Detailed troubleshooting and advanced workflows are provided in AT-406: Applied IAP Inhibitor Workflows; this article highlights up-to-date performance metrics and synergy guidance.

Conclusion & Outlook

AT-406 (SM-406) is a validated, orally bioavailable IAP inhibitor enabling precise apoptosis pathway activation in cancer models. Its nanomolar potency, robust in vivo efficacy, and translational relevance distinguish it for use in apoptosis research and therapeutic development. Continued mechanistic studies—such as those by Yang et al. (2024) resolving FADD-caspase-8-cFLIP complex structure—will refine its application in combinatorial and personalized oncology (Yang et al., 2024). For further reading on next-generation workflows and comparison to other IAP modulators, see AT-406: Next-Gen IAP Inhibitor; this article provides updated clinical benchmarks and mechanistic clarity.